公司本次拟中选的15个药品品种2024年度合计销售额为2.28亿元，占公司2024年度营业收入比例为 15.75%；2025年前三季度合计销售额为1.57亿元(未经审计)，占公司2025年前三季度营业收入比例为 19.25%。若后续签订采购合同并实施，将进一步扩大产品的销量，提高市场占有率，提升公司品牌形 象，对公司未来的经营发展具有积极的影响。 格隆汇2月11日丨一品红(300723.SZ)公布，公司全资子公司广州一品红制药有限公司于近日参加了国家 组织集采药品协议期满品种接续采购办公室组织的国家组织集采药品协议期满品种接续采购的投标工 作。根据接续采购办公室于2026年2月10日发布的《国家组织集采药品协议期满品种接续采购拟中选结 果公示》，公司共计15个药品品种拟中选本次接续采购。 ...

Core Viewpoint - The company, Asia-Pacific Pharmaceutical (002370.SZ), has participated in the continuation procurement organized by the National Organization for Drug Procurement, with 13 products, including injectable Cefmetazole Sodium and Febuxostat tablets, proposed for selection in the continuation procurement process [1] Group 1: Procurement Details - The continuation procurement involves products from the first to eighth batches of the national organized procurement agreements that have expired [1] - The agreed procurement volume for each product will be based on the demand reported by medical institutions, with the selection price gradient determining the volume ratio [1] Group 2: Market Impact - Medical institutions will prioritize the use of the selected drugs from this continuation procurement during the procurement period, ensuring the completion of the agreed procurement volume [1] - If the company signs procurement contracts and implements them, it will further expand the sales of related products, enhance market share, and improve brand influence, positively impacting future operating performance [1]

Core Viewpoint - Changguang Huaxin (688048.SH) reported a significant increase in revenue for the fiscal year 2025, driven by its focus on high-power semiconductor laser technology and expanding market applications [1] Financial Performance - The company achieved an operating revenue of 468.41 million yuan, representing a year-on-year increase of 71.81% [1] - The net profit attributable to the parent company was 19.52 million yuan, while the net profit excluding non-recurring gains and losses was -36.16 million yuan [1] Business Development - The company has been deepening its efforts in the high-power semiconductor laser sector, leveraging its technological advancements and product performance to enhance sales [1] - There has been a steady increase in customer demand, which has supported the growth of sales revenue in this product line [1] Market Opportunities - In addition to consolidating its main business, the company is actively seizing market opportunities in optical communication and laser sensing [1] - Strategic investments in talent, technology, and production lines are beginning to yield results, with the optical communication sector starting to contribute to revenue growth [1] - The advancement in this business area signifies a breakthrough in emerging application markets, diversifying the company's business structure and opening new growth avenues for long-term development [1]

格隆汇2月11日｜晶晨股份(688099.SH)公告称，2025年实现营业总收入67.93亿元，同比增长14.63%；归 属于母公司所有者的净利润8.71亿元，同比增长6.00%。预计2026年第一季度公司营收将实现10%~20% 的同比增长，2026年全年公司营收将实现25%~45%的同比增长，具体业绩存在一定不确定性。 ...

Core Viewpoint - Wufangzhai (603237.SH) announced a restricted stock incentive plan for 2026, proposing to grant a total of 6.999 million shares, which accounts for approximately 3.55% of the company's total share capital at the time of the announcement [1] Summary by Categories Incentive Plan Details - The plan includes an initial grant of 6.2856 million shares, representing about 3.19% of the company's total share capital at the time of the announcement, and 89.79% of the total shares to be granted [1] - A reserve of 714,400 shares is also included, which accounts for approximately 0.36% of the company's total share capital and 10.21% of the total shares to be granted [1]

如何抓住黄金波段机会？聪明钱的选择，黄金+股票一键搞定>> 格隆汇2月11日丨天域生物(603717.SH)公布，自披露本次向特定对象发行A股股票事项以来，公司与相 关中介机构积极推进各项工作。现综合考虑当前宏观经济环境、资本市场环境变化及公司实际情况等诸 多因素，经与相关各方充分沟通、审慎分析后，公司决定终止本次向特定对象发行A股股票事项并撤回 申请文件。公司将持续密切关注资本市场动态，后续根据自身发展需要合理运用多种资本市场工具，助 力公司长期健康发展。 ...

Core Viewpoint - Huajian Group (600629.SH) announced a contract worth RMB 69.481312 million for design services related to the Tianjin High-tech Zone Software and Service Outsourcing Base project [1] Group 1: Contract Details - The contract was signed between Huadong Architectural Design and Research Institute Co., Ltd. and Tianjin Tianxin Huakai Co., Ltd. [1] - The project covers an area of approximately 100,000 square meters with a total construction area of about 846,943 square meters, including 497,156 square meters above ground and 349,787 square meters underground [1] - The building will consist of 117 floors above ground and 4 underground levels, with a total height of 596.70 meters [1] Group 2: Responsibilities - Huadong Institute is responsible for the design and consulting services for all buildings, structures, roads, squares, gardens, and underground facilities within the project boundary [1]

登录新浪财经APP 搜索【信披】查看更多考评等级 格隆汇2月11日丨三美股份(603379.SH)公布，信息披露义务人胡荣达先生于2026年1月23日至2026年2月 11日期间，通过集中竞价交易及大宗交易方式累计减持公司股份795.78万股，占公司总股本的1.30%。 本次减持后，胡荣达先生及其一致行动人合计持有公司股份的比例由61.90%减少至60.60%，权益变动 触及1%刻度。 ...

格隆汇2月11日丨中化岩土(002542.SZ)公布，经公司董事长刘明俊先生提名，董事会提名委员会审查， 侯强先生符合董事会秘书任职资格条件。董事会同意聘任侯强先生为公司董事会秘书，任期自本次董事 会审议通过之日起至本届董事会届满之日止。侯强先生的董事会秘书任职生效后，公司董事长刘明俊先 生不再代行董事会秘书职责。 ...

2025年是端侧智能技术快速发展年,公司不断推出契合市场需求的芯片产品,当前公司各产品线已有超过 20款芯片搭载自研端侧智能算力单元。2025年,搭载自研端侧智能算力单元的芯片出货量已超2,000万 颗，同比增长近160%。与此同时,公司充分发挥平台型SoC技术优势,联合全球智能领域头部客户和新兴 客户,持续推动芯片在创新硬件形态和应用场景上的突破，2025年已有多款适配最新端侧大模型或新应 用场景的新产品上市。 格隆汇2月11日丨晶晨股份(688099.SH)公布2025年度业绩快报，2025年，公司近年来重点投入的新产品 批量上市，快速打开市场局面，公司多年来在全球化市场的持续耕耘逐步进入收获期，经营业绩稳步增 长，经营质量持续提升。2025年全年，公司实现营业收入67.93亿元，同比增加8.67亿元；归属于母公司 所有者的净利润8.71亿元，同比增加0.49亿元；全年芯片销量超1.74亿颗，同比增加超0.31亿颗。2025年 度营业收入、归属于母公司所有者的净利润以及芯片销量均创历史新高。 在2024年"运营效率提升年"的基础上，2025年公司持续推进运营效率提升行动项，2025年公司综合毛利 率逐季提 ...